Geron First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Geron (NASDAQ:GERN) First Quarter 2025 Results

Key Financial Results

• Revenue: US$39.6m (up by US$39.3m from 1Q 2024).
• Net loss: US$19.8m (loss narrowed by 64% from 1Q 2024).
• US$0.03 loss per share (improved from US$0.092 loss in 1Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Geron EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 18%. Earnings per share (EPS) exceeded analyst estimates by 22%.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 7.1% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Geron that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.